August 2, 2023 9:05 am EDT

Following on from a strategic review, Organon ANZ has reshaped its organisational structure to support additional employee development and business growth, through a newly formed Strategy and Business Excellence team that includes Organon ANZ’s first dedicated innovation function.

“We believe that being a leading partner in the health care needs of women supports women as well strengthening the foundations of society,” said Nirelle Tolstoshev, managing director of Organon ANZ.

“As we passed our second anniversary in June this year, we moved into our next phase of growth. It was the right time to review our integration across our business and to ensure we have the future-fit skills and structure required to understand and act on the needs of the health care provider and the patients,” Tolstoshev continued.

Organon has taken an innovative approach to its business, with a newly formed Strategy & Business Excellence team, that are responsible for leading a business which fosters fast-moving innovation and decision making.

The new Strategy & Business Excellence team, which is tasked to deliver on critical areas such as organisational strategy, business development, pipeline planning, data & insights, and customer experience will be headed by Meaghan Clarke. Meaghan brings extensive experience and strong business acumen in the pharmaceutical sector across multiple commercial and therapeutic areas.

“We started Organon with a commitment to listening – to our patients; our customers and our people – and we’ve learned through the employee engagement survey and other feedback mechanisms that our business needed to adapt to continue to anticipate our customers’ needs in a fast-changing market and regulatory environment.  Our business is doing well, and we want to maintain an agility that will continue to build our culture, and to ensure that we continue to attract highly talented people to bring the right skills in-house,” Tolstoshev concluded.

To learn more about Organon, please visit http://www.organon.com/australia and connect with us on LinkedIn.  

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.